SECsense Logo

Reviva Pharmaceuticals 8-K Report: Key Insights on Stock and Warrants Activity

$RVPH
Form 8-K
Filed on: 2025-02-18
Source
Reviva Pharmaceuticals 8-K Report: Key Insights on Stock and Warrants Activity

Based on the provided financial report section, here are the key takeaways:

  1. Company Information:
  • Name: Reviva Pharmaceuticals Holdings, Inc.
  • CIK: 0001742927
  • Location: 10080 N. Wolfe Rd., Suite SW3-200, Cupertino, CA 95014
  • Contact Number: 408-501-8881
  • State of Incorporation: Delaware (DE)
  • SEC Central Index Key (CIK): 001-38634
  • EIN: 85-4306526
  1. Securities Information:
  • Common Stock Symbol: RVPH (traded on NASDAQ)
  • Warrants Symbol: RVPHW (traded on NASDAQ)
  • Class of Stock: Common Stock
  • Warrants: Warrants to purchase one share of Common Stock
  1. Filing Type:
  • Form Type: 8-K
  • Filing Date: February 13, 2025
  1. Reporting Period:
  • Start Date: February 13, 2025
  • End Date: February 13, 2025
  1. Key Dimensions:
  • The report includes explicit members for two segments:
    • Common Stock
    • Warrants to Purchase One Share of Common Stock

Insights:

  • The filing appears to relate to a significant corporate event or transaction, given that it is reported on Form 8-K, which is typically used to announce major corporate events.
  • The presence of warrants indicates that the company might be exploring additional funding options or incentivizing investors.
  • The report indicates a focus on equity instruments, particularly common stock and related warrants, which could imply future dilution or capital raising strategies.

Conclusion:

Reviva Pharmaceuticals is actively engaging with the capital markets, as evidenced by its issuance of common stock and warrants. The filing date and the nature of the report suggest that stakeholders should pay attention to potential developments or announcements that may follow.